(Reuters) - Eli Lilly (LLY) is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by recording nearly $550 million in "pre-launch inventory ...
Eli Lilly is selling higher-dose vials of Zepbound at a lower price to boost weight loss drug access
Eli Lilly on Tuesday released higher doses of its weight loss drug Zepbound in single-dose vials at as much as half its usual monthly list price to reach more patients without insurance coverage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback